J Korean Pediatr Soc Search

CLOSE


Journal of the Korean Pediatric Society 1999;42(4):472-483.
Clinical Trial of Domestically Developed Bovine Lung Surfactant YY-38 in Neonatal Respiratory Distress Syndrome
Chul Lee1, Jeong Nyun Kim2, Min-Soo Park1, Moon Sung Park3, Shin Won Yoon1, Wook Chang1, Ran Namgung1, Kook In Park1, Dong-Gwan Han1
1Department of Pediatrics, Severance Hosp., Yongdong Severance Hosp., Yonsei University
2Department of Pediatrics, Sanggye-Paik Hospital, Inje University College of Medicine
3Department of Pediatrics, Ajou University School of Medicine
신생아 호흡곤란 증후군에서 국내 개발된 Bovine Lung Surfactant YY-38 보충요법의 임상 효과
이철1, 김정년2, 박민수1, 박문성3, 윤신원1, 장욱1, 남궁 란1, 박국인1, 한동관1
1연세대학교 의과대학 소아과학교실
2인제대학교 의과대학 소아과학교실
3아주대학교 의과대학 소아과학교실
Correspondence:  Chul Lee,
Email: 1
Abstract
Purpose
: We previously reported modified bovine lung surfactant YY-38(NewfactanⓇ) had a low surface tension, good hysteresis, and exhibited good pressure-volume curve in animal experiment (J Korean Pediatr Asso 1997;40:771-85). We performed multicenter clinical trial of NewfactanⓇ in neonatal RDS.
Methods
: Seventy-seven infants with RDS(GA 31.8¡¾2.9 wks and BW 1,809¡¾592 gm) in 4 NICU were enrolled. After administration of NewfactanⓇ, we analyzed ventilator parameters and outcomes in 71 infants excluding mortality cases(n=6), and also compared risk factors between response(n=53) and redosing group(n=18).
Results
: NewfactanⓇ was administered at 6.8¡¾7.2 hr after birth. Ventilator parameters such as FiO2, alveolar-arterial oxygen difference(a-A PO2) and oxygenation index(OI) except mean airway pressure(MAP) were significantly improved from six hours after administration. All parameters were improved at 24 hours after administration and persisted for 5 days. Outcomes were as follows; PDA(n=24), BPD(n=16), IVH(n=13), sepsis(n=9), ROP(n=7), pneumothorax(n=4) NEC(n=3), PIE(n=2), and pulmonary hemorrhage(n=1). All patients survived 30 days after birth. Redosing rate was 25%. The incidence of PDA was greater in redosing(56%) than in response group(26 %)(P=0.025).
Conclusion
: In prospective multicenter clinical trial, NewfactanⓇ was effective in the treatment of RDS.
Key Words: Clinical trial, Modified bovine lung surfactant, NewfactanⓇ, , Respiratory distress syndrome


ABOUT
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
AUTHOR INFORMATION
Editorial Office
#1606 Seocho World Officetel, 19 Seoun-ro, Seocho-ku, Seoul 06732, Korea
Tel: +82-2-3473-7305    Fax: +82-2-3473-7307    E-mail: kjpped@gmail.com                

Copyright © 2018 by Korean Pediatric Society. All rights reserved.

Developed in M2community

Close layer
prev next